PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) - NYSEARCA
  • Oct. 13, 2015, 3:49 PM
    • Getting out in front of what should be more bashing of their business models at the Democratic debate tonight, the healthcare names (XLV -1.3%) have about doubled the decline in the S&P 500. Within healthcare, it's the biotechs (IBB -3.1%) and pharmaceuticals (XPH -3.2%) leading the way south.
    • Celgene (CELG -3.3%), Biogen (BIIB -3.6%), Amgen (AMGN -3.5%), Allergan (AGN -4.1%), Mylan (MYL -3.6%)
    • The biotech heavy Russell 2000 (IWM -1.4%) is feeling the pain as well.
    | Oct. 13, 2015, 3:49 PM | 27 Comments
  • Sep. 25, 2015, 3:07 PM
    | Sep. 25, 2015, 3:07 PM | 134 Comments
  • Apr. 8, 2015, 3:23 PM
    • What's the Market Vector Israel ETF (ISRA +2.9%) doing owning a 12% stake in Perrigo? It turns out Perrigo has a stock listing in Tel Aviv as well, thanks to its 2005 purchase of Agis Industries, then Israel's 2nd-largest drug maker.
    • In fact, Perrigo is the only non-Israeli company in the country's benchmark TA-25 Index.
    • The iShares U.S. Pharma ETF (IHE +2.4%) and the PowerShares Dynamic Pharma ETF (PJP +2.5%) are also on the move thanks to Perrigo.
    • Source: Barron's
    • Previously: Mylan makes $205/share bid for Perrigo; Generic firms rally (April 8)
    | Apr. 8, 2015, 3:23 PM | 1 Comment
  • Apr. 4, 2014, 1:12 PM
    | Apr. 4, 2014, 1:12 PM | 6 Comments
  • May 6, 2013, 1:36 PM

    Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses.

    | May 6, 2013, 1:36 PM
  • Sep. 23, 2011, 1:53 PM

    Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy.

    | Sep. 23, 2011, 1:53 PM | 1 Comment
  • Aug. 1, 2011, 3:56 PM

    Citi lowers its price target on Auxilium Pharmaceuticals (AUXL -6.6%) to $22 from $27 saying expectations on revenue from the firm's Xiaflex are too high. Earlier the firm issued its own downward guidance on FY11 revenue derived from the drug to a range of $45M-$50M from $50M-$60M.

    | Aug. 1, 2011, 3:56 PM
  • Aug. 1, 2011, 8:37 AM

    Elan (ELN) shares jump +4.6% premarket after Acorda Therapeutics (ACOR) announces positive prescriber response for its AMPYRA treatment for MS patients. The drug is manufactured by Elan in a supply agreement with Acorda.

    | Aug. 1, 2011, 8:37 AM
  • Jul. 21, 2011, 12:25 PM

    Shares of Alexion (ALXN +8.7%) pop after issuing upward guidance, and announcing it plans to launch its Soliris treatment for patients with aHUS in Q4. (PR)

    | Jul. 21, 2011, 12:25 PM
  • Jul. 21, 2011, 8:20 AM

    Shares of Protalix (PLX) +4.4% premarket after a report says the firm will file a request with the FDA within days for approval of the firm's Gaucher's disease treatment Uplyso.

    | Jul. 21, 2011, 8:20 AM
  • Jul. 12, 2011, 3:48 PM

    Shares of Infinity Pharmaceuticals (INFI +9.6%) pop on above-average volume as the company expands its program to develop new cancer drugs, buying nuisance weeds in western states, unwanted by landowners, but needed by the firm.

    | Jul. 12, 2011, 3:48 PM
  • Jul. 8, 2011, 1:15 PM

    UBS cuts estimates on Alexion Pharmaceuticals (ALXN +3.1%), and lowers its price target to $53 from $55, keeping a Neutral rating on the firm. Shares are outgaining all issues listed on the NASDAQ-100.

    | Jul. 8, 2011, 1:15 PM
  • Jul. 8, 2011, 8:59 AM

    Geron (GERN) releases positive data from a clinical trial of its human embryonic stem cell-based therapy. JPMorgan initiates coverage with an Overweight rating. Shares +5.4% premarket.

    | Jul. 8, 2011, 8:59 AM
  • Jun. 30, 2011, 11:56 AM

    Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively.

    | Jun. 30, 2011, 11:56 AM
PJP Description
The PowerShares Dynamic Pharmaceuticals Portfolio (Fund) is based on the Dynamic Pharmaceuticals Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website
Sector: Healthcare
Country: United States
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub